WuXi PharmaTech Co., Ltd. Schedules Fourth-Quarter 2012 Earnings Release
SHANGHAI, Feb. 8, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2012 after the New York Stock Exchange closes on Thursday, March 7, 2013 (which will be Friday morning, March 8, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Friday, March 8, 2013, to discuss the fourth-quarter 2012 financial results and recent business activities. The conference call may be accessed by calling:
United States: | 1-866-519-4004 |
China (Landline): | 800-819-0121 |
China (Mobile): | 400-620-8038 |
Hong Kong: | 800-930-346 |
United Kingdom: | 0-808-234-6646 |
International: | +65-6723-9381 |
Conference ID: | 99349171 |
A telephone replay will be available two hours after the call's completion at:
United States: | 1-855-452-5696 |
China (Landline): | 800-870-0205 |
China (Mobile): | 400-120-0932 |
Hong Kong: | 800-963-117 |
United Kingdom: | 0-808-234-0072 |
International: | +61-2-8199-0299 |
Conference ID: | 99349171 |
A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com
SOURCE Wuxi PharmaTech Co. Ltd.